Zura Bio Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ZURA research report →
About the company
Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα inhibitor engineered to address conditions influenced by the IL7 and TSLP biological pathways. The company is also advancing Torudokimab, a monoclonal antibody that neutralizes IL-33, which is currently in Phase 2 clinical development.
- CEO
- Sandeep C. Kulkarni
- IPO
- 2023
- Employees
- 30
- HQ
- San Diego, CA, US
Price Chart
- Market Cap
- $336.16M
- P/E
- -4.74
- P/S
- 0.00
- P/B
- 2.67
- EV/EBITDA
- -1.47
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -54.60%
- ROIC
- -37.57%
- Revenue
- $0 · 0.00%
- Net Income
- $-68,650,000 · -31.00%
- EPS
- $-1.06 · -76.67%
- Op Income
- $-75,246,000
- FCF YoY
- -130.64%
- 52W High
- $7.44
- 52W Low
- $1.08
- 50D MA
- $4.51
- 200D MA
- $4.77
- Beta
- 0.03
- Avg Volume
- 1.03M
Get TickerSpark's AI analysis on ZURA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 17, 26 | Mathew Marlyn Teresa | other | 0 |
| Apr 17, 26 | Mathew Marlyn Teresa | other | 11,133 |
| Apr 17, 26 | Mathew Marlyn Teresa | other | 90,000 |
| Apr 17, 26 | Mathew Marlyn Teresa | other | 81,150 |
| Apr 17, 26 | Mathew Marlyn Teresa | other | 66,220 |
| Jun 17, 26 | Jarrett Jennifer | other | 51,000 |
| Jun 17, 26 | Thiara Parvinder | other | 51,000 |
| Jun 17, 26 | Schoch Steven J | other | 51,000 |
| Jun 17, 26 | Nirula Ajay | other | 51,000 |
| Jun 17, 26 | Munshi Amit | other | 51,000 |
Our ZURA coverage
Recent articles, reports, and earnings notes.
No research on ZURA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ZURA report →Similar companies
Peers in the same neighborhood.